Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2022 third-quarter earnings
Image of information being disseminated

What you need to know about Johnson & Johnson’s 2022 third-quarter earnings

Check out this infographic breakdown of the company’s third-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Share Article
share to
Inset - Quarterly Earnings Ribbon

This morning, Johnson & Johnson shared its third-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“The solid results delivered this quarter, including accelerated operational sales* growth in all three of our segments, reflect the strength of our business, versatility of our operations, and the unwavering commitment of Johnson & Johnson’s employees to patients and consumers around the world,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “We invested in R&D at increased levels, advanced our pipeline and returned significant value to shareholders. Looking ahead, we will continue to execute against our long-term strategy, focused on improving health outcomes and access to care.”

For more details about the company’s 2022 third-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.

*Non-GAAP financial measure. Refer to the reconciliations in the full press release.


Q3 2022 Earnings infographic

Johnson & Johnson’s 2022 3rd-Quarter Earnings

Read the earnings press release, which includes full financial data for the third quarter of 2022.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.